Payment overview · 2025
General Payments
$377.66
7 reported records · 4 companies
Healthcare provider profile · identity verified
William Thomas Baker, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LAS CRUCES, NM · NPI 1215913447
Verified facts
What the public records show
CMS Open Payments records show William Thomas Baker, D.O. received $377.66 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.54 | 39.9% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $145.82 | 38.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.69 | 12.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.61 | 9.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.66 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $150.54 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $145.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $129.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.69 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
106 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 690 | 185 |
| Losartan Potassium | Losartan Potassium | 341 | 100 |
| Simvastatin | Simvastatin | 315 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 88 |
| Metformin Hcl | Metformin Hcl | 296 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 75 |
| Lisinopril | Lisinopril | 250 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 70 |
| Gabapentin | Gabapentin | 218 | 67 |
| Potassium Chloride | Potassium Chloride | 203 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 51 |
| Montelukast Sodium | Montelukast Sodium | 185 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 55 |
| Omeprazole | Omeprazole | 147 | 46 |
| Valsartan | Valsartan | 145 | 44 |
| Ozempic | Semaglutide | 134 | 31 |
| Azithromycin | Azithromycin | 131 | 103 |
| Allopurinol | Allopurinol | 130 | 39 |
| Sertraline Hcl | Sertraline Hcl | 125 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 37 |
| Meloxicam | Meloxicam | 117 | 38 |
| Spironolactone | Spironolactone | 116 | 37 |
| Carvedilol | Carvedilol | 111 | 30 |
| Synthroid | Levothyroxine Sodium | 106 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 26 |
| Jardiance | Empagliflozin | 96 | 16 |
| Methylprednisolone | Methylprednisolone | 94 | 76 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 24 |
| Famotidine | Famotidine | 83 | 30 |
| Memantine Hcl | Memantine Hcl | 79 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 16 |
| Glipizide | Glipizide | 72 | 19 |
| Atenolol | Atenolol | 71 | 19 |
| Celecoxib | Celecoxib | 71 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 24 |
| Tramadol Hcl | Tramadol Hcl | 68 | 24 |
| Amoxicillin | Amoxicillin | 66 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 20 |
| Donepezil Hcl | Donepezil Hcl | 62 | 19 |
| Eliquis | Apixaban | 62 | 16 |
| Furosemide | Furosemide | 58 | 21 |
| Trazodone Hcl | Trazodone Hcl | 58 | 12 |
| Azelastine Hcl | Azelastine Hcl | 55 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 13 |
| Nifedipine Er | Nifedipine | 50 | 14 |
| Ibuprofen | Ibuprofen | 48 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 32 |
| Prednisone | Prednisone | 47 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 42 |
| Glimepiride | Glimepiride | 45 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Mupirocin | Mupirocin | 44 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 29 |
| Alprazolam | Alprazolam | 36 | 12 |
| Cephalexin | Cephalexin | 36 | 34 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Gemfibrozil | Gemfibrozil | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 31 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 16 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 26 |
| Estradiol | Estradiol | 29 | 14 |
| Finasteride | Finasteride | 29 | 11 |
| Valacyclovir | Valacyclovir Hcl | 29 | 17 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 20 |
| Fluconazole | Fluconazole | 25 | 16 |
| Cefuroxime | Cefuroxime Axetil | 24 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Tobramycin | Tobramycin | 21 | 18 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Fentanyl | Fentanyl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Triazolam | Triazolam | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Butrans | Buprenorphine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.66 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CREON, FARXIGA, LINZESS, Senza, TRELEGY ELLIPTA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error